Jonathan Goldman, MD

Jonathan Goldman, MD


Health Sciences Clinical Instructor, Department of Medicine, Hematology/Oncology


English, Spanish



Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
Saint John’s Health Center



Hematology-Oncology, UCLA School of Medicine, 2005 - 2008


Internal Medicine, UC San Francisco School of Medicine, 2001 - 2002


MD, Stanford University School of Medicine, 1996


UC San Francisco School of Medicine, 2002 - 2004

Board Certifications

Hematology, American Board of Internal Medicine, 2008
Medical Oncology, American Board of Internal Medicine, 2008
Internal Medicine, American Board of Internal Medicine, 2004

Contact Information

Clinical Interests

Early Drug Development, Hematology, Lung Cancer, Solid Oncology

Scientific Interests

Dr. Jonathan Goldman focuses on lung cancer research and early drug development.

Highlighted Publications

Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Submitted for review.

Goldman JW, Garon EB. Targeting MEK for the treatment of non-small cell lung cancer: a review from the 12th annual targeted therapies of treatment of lung cancer. Journal of Thoracic Oncology, 2012.

Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.

Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar;127(3):343-5.

O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 1991 Aug;3(8):233-40.